New Developments in Parkinson’s Treatment: Anavex Life Sciences’ Progress
Anavex Life Sciences is making significant strides in the treatment of Parkinson’s disease with their investigational therapy, Anavex 2-73. This novel therapy has shown promising results in reducing the severity of both motor and non-motor symptoms associated with Parkinson’s disease dementia. In a recent extension study following the Phase 2 ANAVEX 2-73-PDD-001 trial, participants […]